Drug · CHEMBL32
MOXIFLOXACIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MOXIFLOXACIN. Drugs and targets, record CHEMBL32. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL32
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases53
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| pulmonary tuberculosis | Phase 3 | ClinicalTrials.gov | 28 | 28 | https://conductscience.org/library/drugs?q=MONDO_0006052 |
| tuberculosis | Phase 3 | ClinicalTrials.gov | 26 | 26 | https://conductscience.org/library/drugs?q=MONDO_0018076 |
| multidrug-resistant tuberculosis | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0005861 |
| Helicobacter pylori infectious disease | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0006781 |
| bacterial conjunctivitis | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0006668 |
| chronic obstructive pulmonary disease | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0005002 |
| appendicitis | Unknown | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005649 |
| breast cancer | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| endophthalmitis | Phase 1/2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0016047 |
| fungal keratitis | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0033821 |
1 to 10 of 53Source Open Targets
See all 53 diseasesTrials399
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02410772 | TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens | Phase 3 | 2,516 | 2021-09-28 | moxifloxacin | Its name | ClinicalTrials.gov |
| NCT00864383 | Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis | Phase 3 | 1,931 | 2015-05-25 | moxifloxacin | Its name | ClinicalTrials.gov |
| NCT02800785 | The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial | 1,552 | 2023-04-18 | moxifloxacin | Its name | ClinicalTrials.gov | |
| NCT00759148 | Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis | Phase 3 | 1,179 | 2011-03-22 | moxifloxacin | Its name | ClinicalTrials.gov |
| NCT00348348 | A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis | Phase 3 | 1,161 | 2009-08-13 | moxifloxacin | Its name | ClinicalTrials.gov |
| NCT01573910 | An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients | Phase 3 | 985 | 2015-05-12 | moxifloxacin | Its name | ClinicalTrials.gov |
| NCT00402727 | Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection | Phase 3 | 813 | 2010-01-11 | moxifloxacin | Its name | ClinicalTrials.gov |
| NCT00492726 | Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem | Phase 3 | 804 | 2010-03-03 | moxifloxacin | Its name | ClinicalTrials.gov |
| NCT02813694 | Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia | Phase 3 | 738 | 2019-10-23 | moxifloxacin | Its name | ClinicalTrials.gov |
| NCT02409290 | The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB | Phase 3 | 588 | 2023-09-28 | moxifloxacin | Its name | ClinicalTrials.gov |
1 to 10 of 399
See all 399 trialsComparisons in its trials71
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Antibiotics Therapy Arm vs Appendectomy Arm: Rates of Participants With Appendiceal Cancer | 4 of 776 | 6 of 776 | 1,552 | NCT02800785 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: Total Number of Patients Who Had Resolution of Appendicitis Symptoms at 30 Days | 462 of 676 | 466 of 663 | 1,339 | NCT02800785 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: Number of Participants With at Least One Complications From Treatment | 37 of 676 | 21 of 656 | 1,332 | NCT02800785 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: deaths from any cause | 0 of 676 | 0 of 656 | 1,332 | NCT02800785 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: serious adverse events | 19 of 676 | 19 of 656 | 1,332 | NCT02800785 | Trial comparisons |
| Moxifloxacin AF vs Vehicle: deaths from any cause | 0 of 593 | 0 of 586 | 1,179 | NCT00759148 | Trial comparisons |
| Moxifloxacin AF vs Vehicle: serious adverse events | 0 of 593 | 0 of 586 | 1,179 | NCT00759148 | Trial comparisons |
| Moxifloxacin Solution vs Besifloxacin Suspension: serious adverse events | 1 of 579 | 1 of 582 | 1,161 | NCT00348348 | Trial comparisons |
| Moxifloxacin vs Ofloxacin: serious adverse events | 1 of 489 | 0 of 493 | 982 | NCT01573910 | Trial comparisons |
| Antibiotics Therapy Arm vs Appendectomy Arm: Rate of Participants With Perforated Appendicitis | 59 of 185 | 99 of 621 | 806 | NCT02800785 | Trial comparisons |
1 to 10 of 71
See all 71 comparisons in its trialsPapers from its trials376
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL32
GET https://conductscience.org/api/drugs/v1/CHEMBL32/diseases?page=2